Treatment of medical complications in patients with brain tumors

Current Treatment Options in Neurology

Volumn 7, Issue 4, 2005, Pages 323-336

  Pruitt, Amy A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HEPARIN; HYDROCORTISONE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; MEPREDNISONE; METHOTREXATE; NITROSOUREA; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PREDNISONE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ADRENAL CORTEX ATROPHY; ADRENAL INSUFFICIENCY; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ATAXIA; AWARENESS; BEHAVIOR MODIFICATION; BLEEDING DISORDER; BODY WEIGHT DISORDER; BRAIN EDEMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER PATIENT; CLINICAL TRIAL; COGNITIVE DEFECT; CRANIOTOMY; DEPRESSION; DIET THERAPY; DIPLOPIA; DISEASE EXACERBATION; DROWSINESS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FROZEN SHOULDER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE INTOLERANCE; HAIR LOSS; HEADACHE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; INTRAOCULAR PRESSURE ABNORMALITY; LEG COMPRESSION; LEUKOPENIA; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHUMAN; OSTEOMALACIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PARKINSONISM; PEPTIC ULCER; PHYSICIAN; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; RISK ASSESSMENT; SEIZURE; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STROKE; SYMPTOMATOLOGY; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THRUSH; TREMOR; VENOUS THROMBOEMBOLISM; WITHDRAWAL SYNDROME;

EID: 22544486846     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0042-y     Document Type: Review

References (57)

1. Kaal ECA, Vecht CJ: The management of brain edema in brain tumors. Curr Opin Oncol 2004, 16:593-600.
2. Papadopoulos MC, Saadoun S, Davies DC, et al.: Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001, 15:101-108.
3. Watling CJ, Cairncross JG: Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of 3 cases. J Neurosurg 2002, 97:224-226.
4. Vecht CJ, Hovestadt A, Verbiest HBC, et al.: Dose-effect relation of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 milligrams per day. Neurology 1994, 44:675-680.
5. Meyer G, Badenhoop K: Gluco-corticoid-induced insulin resistance and diabetes mellitus. Receptor, post receptor mechanisms, local cortisol action, and new aspects of anti-diabetes mellitus therapy. Med Klin 2003, 98:266-270.
6. Nielsen GL, Sorensen HT, Mellemkjoer L, et al.: Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 2001, 111:541-545.
7. Batchelor TT, Taylor LP, Thaler HT, et al.: Steroid myopathy in cancer patients. Neurology 1997, 48:1234-1238.
8. Mahindra A, Grossman S: The growing problem of Pneumocystis carinii pneumonia among HIV negative brain tumor patients. Neuro-oncol 2001, 3:361.
9. Thomas CH, Limper AH: Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
10. Kovacs JA, Gill VH, Meshnick S, et al.: New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001, 286:2450-2460.
11. Luyken C, Blumcke I, Fimmers R, et al.: The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003, 44:822-830.
12. Hoang-Xuan K, Capaelle L, Kujas M, et al.: Temozolomide as initial treatment for adults with low grade oligodendroglioma or oligoastrocytoma and correlation with chromosome 1p deletion. J Clin Oncol 2004, 22:3133-3138.
13. Glantz MJ, Cole BR, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
14. Forsyth PA, Weaver S, Fulton D, et al.: Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003, 30:106-112.
15. Vecht CH, Wagner GL, Wilms EB: Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003, 2:404-409.
16. Cohen AD, Reichental E, Halevy S: Phenytoin-induced severe cutaneous drug reactions: suspected interactions with corticosteroids and H2-blockers. Isr Med Assoc J 1999, 1:95-97.
17. Bromfield EB: Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis 2004, 1 (Suppl 1):S27-S33.
18. Walsh DC, Kakkar AK: Thromboembolism in brain tumors. Curr Opin Pulm Med 2001, 7:326-331.
19. Goldschmidt N, Linetsky E, Shalom E, et al.: High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003, 98:1239-1242.
20. Streiff MB, Segal J, Grossman SA, et al.: ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004, 100:1717-1723.
21. Marras LC, Geerts WH, Perry JR: the risk of venous thromboembolism is increased throughout the course of malignant gliomas: an evidence-based review. Cancer 2000, 89:640-646.
22. Bates SM, Kearon C, Crowther M, et al.: A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med 2003, 138:787-794.
23. Stein PD, Hull RD, Patel KC, et al.: D-Dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Intern Med 2004, 140:589-602.
24. Kruip MJHA, Leclercq MGL, Van der Heul C, et al.: Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. Ann Intern Med 2003, 138:941-951.
25. Stevens SM, Elliott CG, Chan KJ, et al.: Withholding anti-coagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med 2004, 140:985-991.
26. Macdonald RL, Amidei C, Lin G, et al.: Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery 1999, 45:245-251.
27. Goldhaber SZ, Dunn K, Gerhard-Herman AM, et al.: Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002, 122:1933-1937.
28. Agnelli G, Piovella F, Buonocristiani P, et al.: Enoxaparin plus compressive stockings compared with compressive stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998, 339:80-85.
29. Iorio A, Agnell G: Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery. Arch Intern Med 2000, 160:2327-2332.
30. Gerlach R, Scheuer T, Beck J, et al.: Risk of postoperative hemorrhage after intracranial surgery post early nadroparin administration: results of a prospective study. Neurosurgery 2003, 53:1028-1035.
31. Leizorovicz A, Goldhaber S: Prospective evaluation of dalteparin efficacy in immobilized patients trial (PREVENT) presented at the Society of Critical Care Medicine's 32nd Annual Critical Care Congress. http://www.theheart.org/index.cfm
32. Carman TL, Kanner AA, Barnett GH, Deitcher SR: Prevention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J 2003, 96:17-22.
33. Schulman S: Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675-683.
34. Tapson VF, Carroll BA, Davidson BL, et al.: The diagnostic approach to acute venous thromboembolism. Clinical practice guidelines. American Thoracic Society. Am J Respir Crit Care Med 1999, 60:1043-1066.
35. Myers TM, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolic disease. Chest 2001, 119(Suppl):S176-193.
36. Bates SM, Ginsberg JS: Treatment of deep-vein thrombosis. N Engl J Med 2004, 268-277.
37. Geerts WH, Heit JA, Clagett GP, et al.: Prevention of thromboembolism (Sixth ACCP Consensus Conference on Antithrombotic Therapy.) Chest 2001, 119(Suppl):S132-1175.
38. Levin JM, Schiff D, Loeffler JS, et al.: Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993, 43:1111-1114.
39. Wen PY, Marks PW: Medical management of patients with brain tumors. Curr Opinion Oncol 2002, 14:299-307
40. Lee AYY, Levine MN, Baker RI, et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
41. Meyer G, Marjanovic Z, Valcke J, et al.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162:1729-1735.
42. Knovich MA, Lesser GJ: The management of thrombembolic disease in patients with central nervous system malignancies. Curr Treat Option Oncol 2004, 5:511-517.
43. Cooper MS, Stewart PM: Corticosteroid insufficiency in acute ill patients. N Engl J Med 2003, 348:727-734.
44. Coursin DB, Wood KE: Corticosteroid supplementation for adrenal insufficiency. JAMA 2002, 287:236-239.
45. Luce JM: Editorial: Physicians should administer low-dose corticosteroids selectively to septic patients until an ongoing trial is completed. Ann Intern Med 2004, 141:70-72.
46. Cestari DM, Weine DM, Oanageas KS, et al.: Stroke in patients with cancer: incidence and etiology. Neurology 2004, 62:2025-2030.
47. Hariharan S, Shapiro W, Chang S, et al.: Phase II randomized dose-ranging trial of human corticotrophin releasing factor in symptomatic brain tumor patients. Neurology 2000, 54:A12.
48. French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004, 62:1252-1260; 1261-1273.
49. Mamon H, Wen PY, Burns A, et al.: Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation. Epilepsia 1999, 40:31-344.
50. Mattson RH: Cognitive, affective, and behavioral side effects in adults secondary to antiepileptic drug use. Rev Neurol Dis 1 (Suppl 1):S10-16.
51. Fugh-Berman AL: Herb-drug interactions. Lancet 2000, 355:1019-1020.
52. Weiger WA, Smith M, Boon H, et al.: Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 2002, 137:889-903.
53. Cesarone MR, Belcaro G, Nicolaides AN, et al.: Venous thrombosis from air travel: the LONFLIT3 study-Prevention with aspirin vs. low-molecular-weight heparin in high-risk subjects. A randomized trial. Angiology 2002, 53:1-6.
54. Chan AT, Atiemo A, Diran LK, et al.: Venous thromboembolism occurs frequently inpatients undergoing brain tumor surgery despite prophylaxis. J Thomb Thrombolysis 1999, 8:139-142.
55. Buller HR, Davidson BL, Decousus H, et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004, 140:867-873.
56. Francis CW, Ginsberg JS, Berkowitz SD, et al.: Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis with or without pulmonary embolism: the THRIVE Treatment Study. Blood 2003, 102:6a.
57. Schulman S, Wahlander K, Lundstrom T, et al.: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelgatran. N Engl J Med 2003, 349:1713-1721.